Organization
Acceleron Pharma, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Acceleron Pharma, Inc.
... On June 28, Celgene and Acceleron announced that their lead product candidate luspatercept (ACE-536) met its primary and ...
... CAMBRIDGE - Acceleron Pharma Inc. (NASDAQ: XLRN) today announced it will host a webcast and conference call ...
... Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call ...
... the two candidates, but the mechanism seems similar to that pursued by Acceleron Pharma with ACE-083, a ligand trap for TGF-beta receptors which is being ...
... Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of ...
... CAMBRIDGE - Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of ...
... Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of ...
... Acceleron and Celgene have the second phase 3 trial they wanted for beta ...
... Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ...
Subscribe now for full coverage on Acceleron Pharma, Inc.
Start My Free Trial